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21 The endometrium is a complex multicellular tissue that is exquisitely sensitive to the actions of sex 
22 steroids synthesised in the ovary (endocrine system). Recent studies have highlighted a previously 
23 under-appreciated role for local (intracrine) metabolism in fine-tuning tissue function in both health 
24 and disease. In this review we have focused on the impact of oestrogens and androgens on 
25 endometrial function summarising data from studies on normal endometrial physiology and 
26 disorders including infertility, endometriosis and cancer. 
27 We consider the evidence that expression of enzymes including aromatase, sulphatase and AKR1C3 
28 by endometrial cells plays an important role in tissue function, and malfunction, and discus results 
29 from studies using drugs targeting intracrine pathways to treat endometrial disorders. We 
30 summarise studies exploring the spatial and temporal expression of oestrogen receptors (ERalpha, 
31 ERbeta and GPER) and their role in mediating the impact of endogenous and synthetic ligands on 
32 cross-talk between vascular, immune, epithelial and stromal cells. There is a single androgen 
33 receptor and androgens play a key role in stromal-epithelial cross talk, scar-free healing of 
34 endometrium during menstruation and regulation of cell proliferation. The development of new 
35 receptor-selective drugs (SERMs, SARMs, SARDs) has reinvigorated interest in targeting receptor 
36 subtypes in treatment of disorders including endometriosis and endometrial cancer and some show 
37 promise as novel therapies. 
38 In summary, understanding the mechanisms regulated by sex steroids provides the platform for 
39 improved personalised treatment of endometrial disorders as well as novel insights into the impact 
40 of steroids on processes such as tissue repair and regeneration.
41
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42 Introduction
43 In women, the endometrium is divided into an inner/luminal functional layer (‘functionalis’) and a 
44 basal layer (‘basalis’). On its inner (luminal) aspect, columnar epithelial cells form a boundary 
45 between the fluid-filled uterine lumen and endometrial tissue containing glands, a well-developed 
46 vasculature, stromal mesenchyme (fibroblasts, perivascular cells) and a diverse population of 
47 immune cells. Between menarche and menopause the endometrium responds to fluctuating levels of 
48 blood borne ovarian sex-steroid hormones (primarily 17ß-oestradiol (E2) and progesterone (P)), 
49 with cyclical proliferation and differentiation ready to support a prospective pregnancy. In a non-
50 pregnant cycle the functional layer is shed during menstruation but within a few days, the luminal 
51 surface is healed and tissue integrity restored ready to resume the next cycle (Garry, et al. 2009)
52 Whilst sex steroid hormones are essential for the maintenance of normal uterine function and 
53 fertility, they may also contribute to the development of hormone-dependent endometrial disorders 
54 that affect millions of women (Table 1). In this review we have focused on the impact of oestrogens 
55 and androgens on the function and malfunction of the endometrium, considering evidence for 
56 expression of receptors that can mediate their function as well as enzymes that modulate local 
57 bioavailability of steroids. The emergence of new classes of drugs that target receptors or enzymes 
58 and offer some potential as novel treatments for endometrial disorders is summarised. 
59 Oestrogen and androgen receptors and their expression in endometrial tissues 
60 Overview of changes in tissue function during the menstrual cycle
61 Based on evaluation of 8000 endometrial biopsies, Noyes et al. (Noyes, et al. 1975) published a 
62 classification of the different stages of the menstrual cycle which is still considered the gold 
63 standard for histological staging. Although cycle length can vary between individuals, staging is 
64 typically based on an average menstrual cycle of 28 days: menstruation (day 1), proliferative phase 
65 (day 4 to 14) and secretory phase (days 16 to 28). Histologically, the functional layer thickens from 
66 about 2 mm recorded immediately after the menstrual phase, to 14 mm prior to ovulation on day 14, 
67 (Hess et al., 2006). Following ovulation and formation of the corpus luteum (CL) there is a rapid 
68 rise in circulating concentrations of P, which stimulates functional transformation of the stromal 
69 fibroblasts (decidualisation) resulting in shape change and reprogramming of gene expression 
70 leading to secretion of factors that regulate immune cell recruitment and receptivity (see 
71 comprehensive review by (Gellersen, et al. 2007). In the absence of a healthy blastocyst, the 
72 regression of the CL results in a rapid decrease in the circulating concentrations of ovarian-derived 
73 steroid hormones (progesterone withdrawal), and triggers a cascade of changes in endometrial 
74 tissue that results in tissue breakdown, piecemeal shedding and synchronous healing during 
75 menstruation (Garry et al. 2009). 
76 Structural and functional features of oestrogen and androgen receptors: genomic and non-genomic 
77 signalling
78 Changes in expression of oestrogen and androgen dependent genes are orchestrated by interaction 
79 of their receptors with DNA binding domains within gene promoters/enhancers as well as non-
80 genomic signalling pathways initiated at the membrane. Steroid receptors contain three key 
81 structure-function domains: a variable amino-terminal domain, a highly conserved DNA-binding 
82 domain (DBD), and a less conserved carboxyl-terminal ligand binding domain (LBD). Differences 
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83 in the sequence of amino acids located within a C-terminal ligand binding pocket play a critical role 
84 in ligand selectivity (Nadal, et al. 2017; Shiau, et al. 1998). A linker region situated between the 
85 DBD and the LBD functions as a flexible hinge with a nuclear localization signal: the proteins also 
86 contain multiple sites for phosphorylation (Lannigan 2003). There are two oestrogen receptors 
87 (alpha and beta) encoded by separate genes, ESR1 and ESR2, respectively: the full length wild-type 
88 proteins they encode (hERα and hERß1 respectively) bind a range of oestrogenic ligands with high 
89 affinity and specificity. Notably analysis of natural ligand reported that whilst 17ß-oestradiol (E2) 
90 bound both receptors with high and equal affinity, oestrone (E1) had higher affinity for wild type 
91 ERß(1) (Zhu, et al. 2006). Multiple splice isoforms of both genes have been identified (reviewed in 
92 (Gibson and Saunders 2012)). ER46 was the first splice variant of human ESR1 described (initially 
93 designated hERα-46; (Flouriot, et al. 2000). ESR2 splice variants including ERß2/bcx and ERß5 are 
94 co-expressed in multiple reproductive tissues and reproductive cancers (Collins, et al. 2009; 
95 Critchley, et al. 2002; Saunders, et al. 2002; Shaaban, et al. 2008). In addition to ESR1 and ESR2 a 
96 family of closely related genes have been identified as encoding ‘estrogen receptor related’ proteins 
97 (ESRR1, ESRR2, ESRR3) which do not bind directly to E1 or E2 as they lack a proper binding 
98 pocket at their C-terminus but which may be activated by cofactors or other lipids (reviewed in 
99 (Gibson and Saunders 2012; Horard and Vanacker 2003)).
100 There is a single androgen receptor gene (AR) located on the X chromosome. Elegant studies, 
101 including those using surface plasmon resonance, have revealed that the long AR N-terminal 
102 domain (NTD) is structurally important for receptor-dependent gene expression (Lavery and 
103 McEwan 2008) and is a promising drug target (Ponnusamy, et al. 2019). Several splice variant 
104 isoforms of AR have been identified with particular attention paid to their role in ligand-
105 independent gene activation in advanced prostate cancers (Dehm and Tindall 2011). Expression of 
106 AR variants including AR-V7 (exons 1/2/3/CE3), has also been reported in primary breast cancers 
107 and breast cancer cell lines (Hickey, et al. 2015) but a literature search did not identify any data 
108 related to their expression in endometrium or endometrial disorders.
109 There have been extensive studies on the functional consequences of steroid ligand binding to ERs 
110 and AR that have been well reviewed elsewhere (Gronemeyer, et al. 2004; McKenna, et al. 1999). 
111 Briefly, ligand binding induces a conformational change in the ligand binding domain, dimerization 
112 and recruitment of co-regulators that play a critical role in regulating the hormonal response. 
113 Ligand-activated receptors can bind directly to DNA sequences within regulatory regions of genes 
114 with sequences that are recognised by oestrogen (ERE – oestrogen response elements) or androgen 
115 (ARE – androgen response elements) receptors having been described (Brodie and McEwan 2005; 
116 Carroll, et al. 2006). Binding studies have also identified a number of so called ‘pioneer’ factors 
117 such as FOXA1 and GATA2 that can enhance direct binding of ER or AR to DNA (Carroll, et al. 
118 2005; He, et al. 2014).   ERs also regulate gene expression through protein-protein interactions with 
119 other transcription factors already bound on DNA (‘tethering’) - examples of tethering mechanisms 
120 include binding to the transcription factor Sp1 which has been implicated in regulation of the 
121 progesterone receptor gene (Petz, et al. 2004) and ERß-dependent induction of gene expression in 
122 human endometrial endothelial cells (Greaves, et al. 2013). 
123 Oestrogens and androgens can also induce changes in cell function following binding to ERs or 
124 ARs localised in the cell membrane. These ‘non-genomic’ signalling cascades can be initiated 
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125 through the membrane localization of the classical receptors following palmitoylation and 
126 interaction with scaffolding proteins or by hormone-responsive G protein-coupled transmembrane 
127 receptors (GPCRs) (Hammes and Levin 2007). One of the most extensively investigated GPCRs is 
128 GPER (originally named GPR 30, also known as GPER1) which was cloned from breast cancer 
129 cells in 1997 and binds oestrogens with nanomolar affinity (Carmeci, et al. 1997). Information on 
130 GPCRs that bind to androgens is less comprehensive but several candidates including GPRC6A 
131 have been identified in cancer cells (Ye, et al. 2019).
132 A recent review provided a useful summary of the wide range of different non-genomic signaling 
133 pathways and how the different genomic and non-genomic pathways may interact (Wilkenfeld, et 
134 al. 2018).
135 Expression and functional impact of oestrogen receptors during the menstrual cycle 
136 We, and others, have used highly specific antibodies to explore temporal and cell specific patterns 
137 of expression of ERα, ERß, ERRs and AR in endometrium during the normal cycle (Critchley and 
138 Saunders 2009; Young 2013). We have documented cell specific and temporal immunoexpression 
139 of full length ERα (ER66) in both normal endometrium and in endometrial pathologies including 
140 cancer (Critchley et al 2002; Collins et al 2008). In full-thickness sections of endometrium (Figure 
141 1) immunoexpression of ERα is intense in the epithelial glands and in the stroma of both the 
142 functional and basal layers: endothelial cells lining the blood vessels appear immuno-negative 
143 (Critchley, et al. 2001). Expression is down-regulated in the functional layer during the secretory 
144 phase in response to the rising levels of progesterone (Figure 1. (Lessey, et al. 1988; Young 2013). 
145 We have recently explored expression of ER46 in the endometrium using a combination of 
146 immunohistochemistry and Western blotting (Gibson, et al. 2020). Notably the variant protein was 
147 co-localised with ER66 in cell nuclei during the proliferative phase with striking expression in a 
148 population of uterine natural killer cells (uNK) implicated in vascular remodelling (Gibson, et al. 
149 2015; Quenby, et al. 2009). 
150 Studies in mice suggest a complex role for ERα in epithelial and stromal compartments of the 
151 endometrium. For example, the role of epithelial ERα was studied using a conditional knockout 
152 mouse which were ovariectomised and then treated with a single intraperitoneal injection of 0.25 μg 
153 17β-estradiol (E2) in 100 μl sesame oil. Analysis of samples recovered 2, 24 or 72h after E2 
154 injection revealed that epithelial ERα was dispensable for the proliferative response observed 2h but 
155 essential for responses at 24 and 72h (Winuthayanon, et al. 2014). Similar studies also revealed a 
156 critical role for ERα in paracrine regulation of stromal decidualization in this species (Pawar, et al. 
157 2015). The pattern of expression of ERß is distinct from that of ERα with highest concentrations of 
158 mRNA encoding full length ERß1 in the secretory phase and immunoexpression in epithelial, 
159 stromal, endothelial cells and immune cells (Critchley et al. 2001): ERß1 is not downregulated in 
160 the functional layer during the secretory phase (Bombail, et al. 2008). Studies in mice with Esr2 
161 knockout have suggested a less striking phenotype than in the Esr1 knockout although a re-
162 evaluation of the evidence by Hapangama et al (Hapangama, et al. 2015) concluded that sustained 
163 E2 stimulation of endometrial epithelial cells via ERß might induce apoptosis. There has been some 
164 disagreement about the cyclical expression (or otherwise) of ERß in endometrial endothelial cells 
165 ((Critchley et al. 2001; Lecce, et al. 2001). A our own study using endothelial cells from different 
166 vascular beds demonstrated those originally isolated from endometrium or myometrium were 
Page 5 of 32
joe@bioscientifica.com
Manuscript submitted for review to Journal of Endocrinology
For Review Only
Androgens, oestrogens and endometrium
6
167 ERß+/ERα- and revealed cell-specific impacts of an ERß-selective agonist on gene expression 
168 (Greaves et al. 2013). In contrast studies using isolated human uNK cells suggest their response to 
169 oestrogens may be complex involving rapid membrane-initiated signaling via ER46 (Gibson et al. 
170 2020) and/or binding to ERß (Gibson et al. 2015). Treatment of isolated uNK cells with either 
171 oestrone (E1) or E2 promotes cell migration and secretion of chemokine (C-C motif) ligand 2 
172 (CCL2) (Gibson et al. 2015). These studies highlight the importance of endogenous oestrogens in 
173 the dynamic interplay between different endometrial cell types that play a critical role in 
174 preparation for pregnancy. 
175 Expression of proteins encoded by human ESR2 splice variant mRNAs (ERß2, ERß5) has been 
176 detected in human endometrial cells (Collins, et al. 2019; Collins et al. 2009; Critchley et al. 2002). 
177 Notably these variants may also be present in primates (Sierens, et al. 2004) but are not expressed in 
178 rodents. In vitro studies have demonstrated the variants can have a functional impact on endometrial 
179 cell function by forming heterodimers with full-length isoforms (Collins et al. 2019). Expression of 
180 ERRs has also been detected in human endometrium with cell-based studies, highlighting the 
181 potential for them to alter cell metabolism or ERα-dependent cell functions (Bombail, et al. 2010a; 
182 Bombail, et al. 2010b)
183 Plante et al (Plante, et al. 2012) examined expression of GPER in endometrium using RT-qPCR and 
184 immunohistochemistry reporting maximal expression in the proliferative phase. An earlier study by 
185 Kolkova et al (Kolkova, et al. 2010) claimed protein expression was less variable than the mRNA 
186 and immuno-staining was more intense in the epithelial cells than stroma throughout the cycle. 
187 GPER may be involved in neoplastic transformation of endometrium (Jacenik, et al. 2016) or in 
188 promotion of HIF1α-induced expression of MMPs in endometrial stromal cells in women with 
189 endometriosis (Zhang, et al. 2017). A number of GPER knockout mice have been generated using 
190 different targeting strategies: females are fertile with no obvious reproductive defects although 
191 impacts on obesity and vasculature have been claimed (Prossnitz and Hathaway 2015).  
192 Expression and functional impact of androgen receptors during the menstrual cycle 
193 Immunostaining for AR in full thickness endometrial tissue sections (Figure 1, (Marshall, et al. 
194 2011)) detected intense staining in stromal fibroblasts which exhibited cyclical variation in the 
195 functional layer but remains unchanged within the basal compartment across the cycle. How this 
196 difference in expression within closely adjacent cells is regulated remains unknown. Epithelial cells 
197 in the functional layer upregulate expression of AR in response to falling levels of progesterone in a 
198 normal cycle or following administration of anti-progestins and this is associated with reduced 
199 proliferation (Marshall et al. 2011; Narvekar, et al. 2004). We have identified androgen-regulated 
200 genes in primary human endometrial stromal cells several of which (e.g. CITED2, HIF1a, CD44) 
201 are implicated in networks that protect cells against stress and apoptosis (Marshall et al. 2011). 
202 These data coupled with the observation that AR expression remains unchanged in the stromal cells 
203 of basal compartment at time of menses (Garry et al. 2009) prompted us to investigate whether 
204 androgens might also play a role in regulating endometrial breakdown and repair using a mouse 
205 model that recapitulates key features of menstruation in women (Cousins, et al. 2016a; Cousins, et 
206 al. 2016b; Cousins, et al. 2014). In this model, administration of a single injection of DHT at the 
207 time of progesterone withdrawal to induce menstruation had a striking impact on both tissue 
208 breakdown and restoration of tissue homeostasis. Although our understanding of the role of 
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209 androgens in endometrial tissue function is still incomplete, we identified changes in expression of 
210 matrix metalloproteinases (MMP3, 9) which are implicated in breakdown of human endometrium 
211 (Cousins et al. 2016a). 
212 Expression of enzymes implicated in biosynthesis and metabolism of oestrogens and 
213 androgens in endometrial tissue 
214 In recent years there has been a rapid increase in evidence to support a role for local tissue 
215 (‘intracrine’) regulation of endometrial steroids (Gibson, et al. 2013; Gibson, et al. 2018a; Gibson, 
216 et al. 2016a). Key findings have included direct measurement of steroids in endometrial tissue 
217 homogenates recovered during the menstrual cycle: notably Huhtinen and colleagues reported they 
218 did not parallel those in blood (Huhtinen, et al. 2014; Huhtinen, et al. 2012). In women (but not in 
219 mice) the adrenals are an important source of sulphated steroids that circulate at high concentrations 
220 in the blood but are unable to bind directly to the steroid receptors. A brief summary of enzymes 
221 detected in endometrial tissue and their substrates is provided in Figure 2 with a few 
222 complementary references discussed below. Readers interested in the topic of intracrine steroids are 
223 recommended to read the comprehensive review by Konings et al which includes a systematic 
224 search for papers reporting expression of steroidogenic enzymes in pre- and postmenopausal 
225 endometrium (Konings, et al. 2018).
226 Briefly, a strong case has been made that the ‘inactive’ adrenal steroid dehydroepiandrosterone 
227 (DHEA) is an important precursor of bioactive androgens in women (Labrie, et al. 2005), a 
228 proposal which has been supported by detection of all the enzymes that regulate conversion of 
229 DHEA via intermediates to T, DHT or oestrogens (Gibson et al. 2013; Gibson et al. 2016a; Gibson, 
230 et al. 2018b). Catalano and colleagues reported increased expression of AKR1C3 in the early 
231 secretory phase (Catalano, et al. 2011), consistent with results obtained using an in vitro model of 
232 stromal decidualisation (Gibson et al. 2016a). Inter-conversion of active/inactive oestrogens and 
233 androgens is mediated via 17β-hydroxysteroid dehydrogenase isozymes, of which several isoforms 
234 are expressed in endometrium. For example, 17βHSD type 1 is responsible for production of T and 
235 E2, from A4 and E1, respectively, whereas 17βHSD2 catalyses the opposite reaction. HSD17B2, is 
236 expressed in glandular epithelial cells is markedly increased in the secretory phase (Maentausta, et 
237 al. 1991) reported overexpression of 17βHSD2 is a feature of endometrium in women with 
238 disorders such as endometriosis, adenomyosis, and/or leiomyomas (fibroids) rather than those who 
239 are disease-free (Kitawaki, et al. 2000). 
240 Expression of steroid sulphatase (STS) in endometrial tissue can catalyse conversion of DHEAS to 
241 DHEA (Figure 2) but can also increase the concentration of E1 by removal of sulphate moieties 
242 from E1S. Using an in vitro model of decidualisation we have confirmed expression of both STS 
243 and aromatase (CYP19A1) in endometrial stromal cells with evidence that both enzymes contribute 
244 to production of oestrogens during decidualisation (Gibson, et al. 2018a; Gibson et al. 2013).
245 Endometrial Disorders: altered expression of enzymes and receptors implicated in disease 
246 aetiology
247 Implantation Failure and Recurrent Miscarriage
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248 Timely and efficient decidualization of endometrial stromal cells in response to ovarian-derived 
249 progesterone is essential for the generation of an endometrial microenvironment that can support 
250 and nurture the implanting blastocyst.  Disruption of decidualization is implicated in implantation 
251 failure and miscarriage. Studies in mice using aromatase inhibitors (AI) demonstrated local intra-
252 uterine production of E2 is critical for establishment of pregnancy (Das, et al. 2009). In women, E2 
253 is produced during decidualisation of endometrial stomal cells which regulates uNK cell migration 
254 (Gibson et al. 2020; Gibson et al. 2015). Given the evidence that disturbances in the 
255 numbers/location of uNK cells can predispose women to experiencing a miscarriage (Lash, et al. 
256 2016) these data are consistent with a role for E2 in regulating the endometrial microenvironment 
257 during the establishment of pregnancy.
258 We have demonstrated that during in vitro decidualisation of primary human endometrial stromal 
259 cells there is a significant increase in the expression of AKR1C3, the enzyme responsible for the 
260 conversion of androstenedione to testosterone, which is also accompanied by increased secretion of 
261 testosterone into the culture medium (Gibson et al. 2016a). In addition, blocking AR action using 
262 flutamide during in vitro decidualisation revealed a role for AR-mediated gene expression of 
263 osteopontin, a protein implicated in receptivity (Gibson et al. 2016a). Further studies using primary 
264 human endometrial stromal cells from women of advanced reproductive age suggested that the age-
265 related decline in adrenal steroids may have an impact on the ability of the endometrium to support 
266 a pregnancy and that increased availability of adrenal precursors enhanced androgen production and 
267 secretion of decidualisation markers (Gibson et al. 2018b). Intravaginal supplementation with 
268 DHEA has shown promising results in alleviating postmenopausal vaginal dryness and atrophy in 
269 clinical trials without any adverse effects (Labrie 2018) but delivery into the endometrium of 
270 premenopausal women has not been tested. Other studies have reported a positive impact of DHT 
271 on stromal cell decidualisation and resistance to oxidative stress (using hydrogen peroxide) 
272 (Kajihara, et al. 2012) expanding our understanding of the potentially beneficial role of androgens 
273 as direct modulators of endometrial function as well as precursors of oestrogen biosynthesis (see 
274 review by (Gibson, et al. 2016b).
275 Failure to downregulate ERα during the secretory phase (see Figure 1 and discussion above) has 
276 been reported in women with defects in uterine receptivity (Lessey, et al. 2006). A complementary 
277 study using samples from women with unexplained infertility also showed that in these patients 
278 elevated expression of ERα in the mid-luteal phase was associated with reduced expression of 
279 glycodelin-A, low levels of which have been implicated in recurrent implantation failure 
280 (Dorostghoal, et al. 2018). There is no information about dysregulation of ERß in implantation 
281 failure. Fertility problems in women with polycystic ovaries and excess androgens might relate to 
282 overstimulation of AR signalling pathways but currently the evidence is quite limited (Schulte, et 
283 al. 2015).
284 Endometrial cancer
285 The majority of endometrial cancers (EC) present with abnormal endometrial bleeding in 
286 postmenopausal women: rates are rising particularly in younger women, with obesity considered a 
287 significant contributing factor (Table 1. Reviewed by (Sanderson, et al. 2017). EC are historically 
288 classified as type 1 or type 2; type 1 is the most commonly diagnosed form (about 80% of the 
289 cases), is considered oestrogen-dependent and characterised by hyperplastic proliferation of the 
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290 endometrial glands. A large number of studies have investigated the source and impact of 
291 oestrogens in endometrial cancer with landmark papers including those by Sasano and collaborators 
292 who reported evidence of increased immunoexpression of aromatase, STS and 17βHSD enzymes in 
293 both endometrial hyperplasia and EC (Sasano, et al. 1996; Utsunomiya, et al. 2004; Utsunomiya, et 
294 al. 2001). A recent comprehensive systematic review considered the evidence that intracrine 
295 metabolism contributes to EC (Cornel, et al. 2019). The authors highlighted the importance of 
296 sulphatase and aromatase enzymes in the generation of E1 and E2 within endometrial cancer tissue 
297 in promoting a pro-oestrogenic environment favouring proliferation of epithelial cells (Cornel et al. 
298 2019). The authors sounded a note of caution by highlighting the variability between individuals 
299 and methodologies which may explain some variations in drug responses (discussed below). 
300 The best evidence for an impact of androgens on EC risk has come from studies in women with 
301 polycystic ovarian disease where the risk of type 1 cancers is higher in women with symptoms of 
302 androgen excess such as hirsutism and irregular periods (Fearnley, et al. 2010). Tanaka et al 
303 reported DHT was elevated in endometrioid endometrial adenocarcinoma tissues compared with 
304 that in normal endometrial tissues (8.0-fold) in a group of 41 patients (Tanaka, et al. 2015). These 
305 results have been complemented by reports that AKR1C3 (conversion from A4 to T) and 5α-
306 reductase (reduction of T to DHT) are both expressed in EC (Gibson et al. 2018a; Ito, et al. 2016). 
307 Expression of ERα, ERß1 and splice variant isoforms of ERß (ERß2, ERß5) in EC have been 
308 documented (Collins et al. 2019; Collins et al. 2009). In a recent paper we highlighted the potential 
309 that ERß5, a variant unable to bind directly to E2, may still influence the response of EC to 
310 oestrogens by forming heterodimers with ERα (Collins et al. 2019). High GPER expression is 
311 predictive of poor survival in endometrial cancers (Smith, et al. 2007). Prossnitz and colleagues 
312 have reported interesting results using ERα-negative/GPER-positive cells which suggest activation 
313 of downstream signalling in response to SERMs such as Tamoxifen may explain why women 
314 treated with this drug are at higher risk of EC (Petrie, et al. 2013). We, and others, have reported 
315 widespread expression of AR in EC (reviewed in (Gibson, et al. 2014)). Evidence that loss of AR is 
316 associated with poorer prognosis, reports that AR was elevated in metastases (Kamal, et al. 2016), 
317 and that androgens may be anti-proliferative in EC cells have raised the prospect that SARMs 
318 should be explored for this cancer as well as those of breast (see below). There are no reports of AR 
319 variants being expressed in EC. 
320 Endometriosis
321 Endometriosis is an oestrogen-dependent neuroinflammatory pain disorder characterised by the 
322 presence of ‘lesions’ of endometrial-like tissue in sites outside the uterus (Horne and Saunders 
323 2019). Endometriosis and adenomyosis are often found in the same patient and may share a 
324 common aetiology (Yovich, et al. 2019). Infertility is a common co-morbitity of endometriosis and 
325 differences between expression profiles of mRNAs, microRNAs and proteins in endometrial 
326 biopsies from controls and women with endometriosis have been reported (Burney, et al. 2009; 
327 Burney, et al. 2007) and have recently been reviewed (Bulun, et al. 2019). Notably there remain 
328 differing views as to whether receptivity is or is not affected (Lessey and Kim 2017; Miravet-
329 Valenciano, et al. 2017). Studies comparing the impact of a decidualisation stimulus on isolated 
330 endometrial stromal cells have reported alterations in the expression of steroidogenic enzymes in 
331 cells from women with endometriosis (Aghajanova, et al. 2009). Blunted responses to progesterone, 
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332 often termed ‘progesterone resistance’, are considered a hallmark of the disorder (Aghajanova, et al. 
333 2010; Bulun, et al. 2010). Some have questioned whether this property is an innate feature of the 
334 eutopic endometrial cells or acquired when they grow in ectopic sites (McKinnon, et al. 2018).
335 Some of the best evidence for the importance of intracrine action of steroids has come from studies 
336 comparing concentrations of steroids in lesions and eutopic endometrium in women with 
337 endometriosis (Huhtinen et al. 2014; Huhtinen et al. 2012). To complement mass spectrometry data, 
338 expression of enzymes in lesions such as aromatase, AKR1C3 and STS has been measured with 
339 evidence that their over-expression is responsible for generation of a lesion tissue environment rich 
340 in oestrogens that can bind ERs or GPER (Rizner 2009, 2016). Notably, aromatase appears to be 
341 involved in local biosynthesis of both E2 and the pro-inflammatory regulator prostaglandin E2 
342 (Attar and Bulun 2006). Upregulation of ERß is also considered a hallmark of the altered 
343 microenvironment of lesions, which may promote the impact of oestrogens on inflammation, 
344 angiogenesis or pain pathways (Bulun, et al. 2012; Greaves, et al. 2014a; Greaves, et al. 2014b).
345 Adenomyosis
346 Adenomyosis is a condition characterised by the presence of heterotopic endometrial glands and 
347 stroma within the myometrium and has traditionally been difficult to diagnose as it can present with 
348 symptoms such as infertility, pain and heavy menstrual bleeding, which are also characteristics of 
349 other conditions, including endometriosis and fibroids (Pontis, et al. 2016). Recent advances in 
350 imaging offer hope for improved understanding of its presentation and pathogenesis (Chapron, et al. 
351 2020).  Altered gene expression in the endometrium of women with adenomyosis has been reported 
352 although results have been based on small numbers of samples (Herndon, et al. 2016; Xiang, et al. 
353 2019). It has been suggested that development of adenomyosis may involve mechanisms activated 
354 but not resolved during endometrial tissue injury with a common aetiology to some forms of 
355 endometriosis (Donnez, et al. 2019; Donnez, et al. 2018). Studies using tissue recovered from 
356 women with adenomyosis have identified increased expression of GPER and some association 
357 between GPER polymorphisms with the disease, however, it must be noted that study populations 
358 have been small (Hong, et al. 2019; Li, et al. 2017). In vitro studies have identified pathways 
359 promoting E2-induced overproliferation of uterine smooth muscle cells from women with 
360 adenomyosis (Sun, et al. 2015). Immunostaining of tissue sections from adenomyosis uteri have 
361 detected changes in ERα, reduced PR and elevated expression of ERβ (Mehasseb, et al. 2011) and 
362 aromatase (Barcena de Arellano, et al. 2013) all consistent with an oestrogen-dependent disease. In 
363 older papers, expression of AR has been reported (Horie, et al. 1992).
364 Drugs targeting sex steroid metabolism 
365 Aromatase inhibitors
366 An excellent historical summary of the discovery of aromatase, identification of increased 
367 expression in quadrants of breast containing a tumour, and the development and refinement of 
368 aromatase inhibitors (AIs) has been published by leaders in the field (Santen, et al. 2009).  The 
369 development of highly effective 3rd generation AIs (anastrozole, letrozole, exemestane) led to 
370 clinical trials for a number of indications including postmenopausal breast cancer, gynaecomastia in 
371 men and ovarian cancer (Langdon, et al. 2017; Miller, et al. 2001; Santen et al. 2009). One key 
372 reproducible finding has been a lower rate of EC and venous thrombosis in women treated with AIs 
373 compared with those treated with Tamoxifen (Chlebowski, et al. 2015). The ClinicalTrials.gov 
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374 website lists 22 trials with search terms endometrial cancer+aromatase inhibitor with the main focus 
375 being on women with more advanced disease. Many trials are not yet completed but evidence of 
376 benefit in some ER+ cancers has been reported. For example, in 40 women treated with 
377 exemestane, there was remission in 10% and lack of progression after 6 months in 35% of the 
378 patients (Lindemann, et al. 2014). The PARAGON trial a phase 2 open label study using anastazole 
379 in 82 patients with ER and/or PR positive hormonal therapy naive metastatic endometrial cancer 
380 reported clinical benefit in 44% (Mileshkin, et al. 2019) although results from other trials have been 
381 disappointing and may have been influenced by obesity in the target population (van Weelden, et al. 
382 2019). Some promising results have been reported following treatment of women with the rarer 
383 cancer low grade endometrial sarcoma with AIs (reviewed in (Pannier, et al. 2019). 
384 Letrozole and anastrozole have also been evaluated in both pre- and postmenopausal women with 
385 endometriosis (Pavone and Bulun 2012). These authors propose that AIs appear to be a suitable 
386 therapy for endometriosis-associated pain in women who are postmenopausal by targeting the 
387 intracrine oestrogen biosynthesis that contributes to sustained symptoms in this age group. Recent 
388 advances have included development of vaginal ring delivery systems for co-administration of 
389 anastrozole and the androgenic progestin levonorgestrel (LNG) as a potential therapy for 
390 endometriosis associated pain: a phase I trial reported promising findings (Schultze-Mosgau, et al. 
391 2016). Whilst these results seem promising a recent ESHRE guideline that considered whether AIs 
392 should be given in combination with contraceptives or other therapies concluded that due to side 
393 effects they should only be prescribed to women after all other options for medical or surgical 
394 treatment are exhausted (Dunselman, et al. 2014). AIs have also been suggested as therapies for 
395 adenomyosis but with the caveat that further studies are required (Vannuccini, et al. 2018). 
396 Sulphatase inhibitors
397 A number of potent STS inhibitors have been developed with the primary indication being 
398 treatment of hormone-dependent cancers (Day, et al. 2009; Purohit and Foster 2012). The 
399 compound STX64 (Irosustat) was effective in blocking oestrogen synthesis in endometrial cancer 
400 cells in vitro and was tested as a therapy for advanced endometrial cancer before being discontinued 
401 as a mono-therapy by Ipsen (Pautier, et al. 2017). Irosustat has recently been used as an addition to 
402 aromatase inhibitors in women with advanced ER+ breast cancer and reported as having a positive 
403 clinical impact (Palmieri, et al. 2017). Another inhibitor, estradiol-3-O-sufamate (E2MATE) has 
404 been reported which deceased STS activity in human endometrial explants and decreased lesion 
405 weight and size but did not alter systemic oestrogens in a mouse model of endometriosis (Colette, et 
406 al. 2011). E2MATE, under the trade name PGL2001, has been shown to reduce STS activity in 
407 endometrium when given once a week for 4 weeks (Pohl, et al. 2014) the same drug was used in a 
408 trial for treatment of endometriosis-associated pain [NCT01631981] but results have not been 
409 reported. 
410 Hydroxysteroid dehydrogenase inhibitors
411 17ßHSD1 inhibitors were originally developed to target the biosynthesis of bioactive E2 in 
412 hormone-dependent breast cancer (Day, et al. 2008). Recently, with evidence for expression of 
413 17ßHSD1 in endometriosis lesions, their use has been expanded to treatment of endometriosis with 
414 promising results reported (Delvoux, et al. 2014). The role of 17ßHSD5/AKR1C3 in metabolism of 
415 both steroids and prostaglandins implicated in endometriosis-associated pain have make it an 
Page 11 of 32
joe@bioscientifica.com
Manuscript submitted for review to Journal of Endocrinology
For Review Only
Androgens, oestrogens and endometrium
12
416 attractive target as a novel therapy for this disorder. A number of inhibitors have been developed 
417 with the Bayer compound BAY1128688 showing sufficient promise for it to be used in a phase 2 
418 randomised clinical  trial to assess efficacy of different doses in 121 women with symptomatic 
419 endometriosis. The trial [NCT03373422] was terminated after 8 months due to an increased 
420 incidence of liver toxicity highlighting the challenge of developing drugs that may target enzymes 
421 present in multiple tissues (van Weelden et al. 2019). In their recent review Rizner and Penning 
422 (Rizner and Penning 2020) concluded the ‘hepatotoxicity the effect was probably compound related 
423 which does not preclude AKR1C3 as a target’ and development of other drugs targeting this 
424 enzyme alone or in combination with other targets is continuing (Wangtrakuldee, et al. 2019)
425 Dual/combined targeting
426 Whilst initial studies have focused on mono-therapies, a new generation of drugs with dual actions 
427 has also been developed – examples include those that target aromatase and STS (DASI, (Purohit 
428 and Foster 2012)) or STS and 17βHSD1. Whilst some in vitro studies seem promising, clinical 
429 trials are yet to be completed (reviewed in (Potter 2018)).
430 Drugs targeting oestrogen and androgen receptors and their potential to treat endometrial 
431 disorders
432 The solving of the crystal structure of nuclear ERs as well as detailed modelling of the impact of 
433 ligand binding on conformation, recruitment of co-factors and gene expression laid the foundation 
434 for the development of synthetic ligands that exhibit selectivity, tissue-specific agonism, 
435 antagonism or induce receptor degradation; a comprehensive perspective and background is 
436 provided by Burris et al 2013 (Burris, et al. 2013). Table 2 summarises the specificities and 
437 properties of some of the novel non-steroidal ligands developed to target ERs and AR a number of 
438 which have been investigated in the context of endometrial disorders and are discussed below.
439 Oestrogen receptors
440 Agonists and antagonists with selectivity for ERα, ERß and GPER have been validated using a 
441 range of cell based and animal models (Table 2). When Frasor et al (Frasor, et al. 2003) compared 
442 the effect of 4x daily injections of 4,4',4''-(4-Propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol (PPT) or 
443 2,3-bis(4-Hydroxyphenyl)-propionitrile (DPN) to immature (d21) female mice, they noted 
444 differences in tissue response which they attributed to activation of ERα or ERß respectively. PPT 
445 caused epithelial cell proliferation, increased uterine weight and expression of lactoferrin but 
446 decreased Ar mRNA. In contrast, DPN did not increase uterine weight or luminal epithelial cell 
447 proliferation but appeared able to reduce stimulation by PPT. These findings are consistent with a 
448 large body of work that implicates ERα as the major regulator of oestrogen-dependent proliferation 
449 in the uterus (Hewitt and Korach 2003; Winuthayanon, et al. 2017). In contrast, it appears that ERß 
450 may have other functions including specific roles in inflammation and angiogenesis (Critchley et al. 
451 2001; Gibson et al. 2015; Gibson and Saunders 2012; Greaves et al. 2013). There have been fewer 
452 studies focussed on GPER but when Zhang et al (Zhang et al. 2017) treated primary endometrial 
453 stromal cells with E2, G1 ((±)-1-[(3aR*,4S*,9bS*)-4-(6-Bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-
454 tetrahydro-3H-cyclopenta[c]quinolin-8-yl]- ethanone) or G15 ((3aS*,4R*,9bR*)-4-(6-Bromo-1,3-
455 benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta[c]quinolone), they reported that stimulation of GPER 
456 with G1 mimicked the impact of E2 and resulting in stabilisation of HIF protein and increased 
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457 expression of VEGF and MMP9. The Prossnitz group generated a GPER antagonist (G36, (±)-
458 (3aR*,4S*,9bS*)-4-(6-Bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-tetrahydro-8-(1-methylethyl)-3H-
459 cyclopenta[c]quinolone, Table 2) with improved selectivity and reported that it can block multiple 
460 E2-mediated second messenger signalling pathways and endometrial cell proliferation (Dennis, et 
461 al. 2011).
462 Selective oestrogen receptor modulators (SERMs) were developed to treat ERα-positive breast 
463 cancers with the ideal SERM being one that acts as an antagonist in breast but an agonist in bone 
464 (Burris et al. 2013). The evolution in our understanding of tissue selective activities of ligand-
465 activated receptors coupled with the discovery of different ER subtypes and splice variants has 
466 resulted in several generations of SERMs. Tamoxifen is a first generation SERM that displays 
467 agonism in the endometrium, increasing EC risk; second generation SERMs such as Raloxifene do 
468 not agonize endometrial growth and are associated with lower risk of EC and may have additional 
469 positive effects on cognition and the cardiovascular system (Muchmore 2000). Other SERMs have 
470 a mixture of agonist/antagonist activity in endometrium, agonist activity in bone and antagonism in 
471 breast (Pickar, et al. 2018). 
472 Selective oestrogen receptor degraders (SERDs) antagonize ERα and induce its degradation, 
473 resulting in a decrease in ERα protein levels: they do not show agonist properties in other tissues 
474 (Kieser, et al. 2010). Fulvestrant was the first SERD to be approved as a therapeutic and is 
475 commonly used as a treatment for advanced breast cancer (Blackburn, et al. 2018). Although 
476 originally marketed under the trade name Faslodex by AstraZeneca manufacture of generic versions 
477 has been approved by the US Federal Drugs Administration.  A number of new generation SERDs 
478 are in development (Pepermans and Prossnitz 2019) one of which is bazedoxifene (BZA) a 
479 compound which exhibits SERD properties in breast cancer with beneficial properties in bone and 
480 no adverse impact on endometrium leading to its approval for hormone replacement therapies 
481 (Pickar et al. 2018). Recent mechanistic studies suggest BZA may be useful in treating cancers 
482 which contain ERα mutants (Fanning, et al. 2018). In addition to activation by endogenous 
483 oestrogens there is evidence that GPER may also be activated by SERMs/SERDs developed to 
484 target ERα which may explain some apparent discordant results in ERα negative cancers (see 
485 review by (Meyer, et al. 2011).
486 Androgen receptors
487 Selective androgen receptor modulators (SARMs) have been developed to support the beneficial 
488 impacts of AR-mediated cell function in bone and muscle without the adverse side effects seen with 
489 high doses T or DHT (gynaecomastia, aggression, prostate hyperplasia) (Burris et al. 2013; 
490 McEwan 2013) (Table 2). New generation SARMs have been proposed as therapeutics for women 
491 suffering from breast cancer, muscle wasting or urinary incontinence and a number of clinical trials 
492 have been undertaken to evaluate their use for these indications (Brodie and McEwan 2005; Dalton, 
493 et al. 2011).
494 Targeting oestrogen receptors in endometrial disorders
495 A high proportion of low grade EC express ERα as well as progesterone receptors. In a recent 
496 systematic review van Weelden and colleagues highlighted the progestins as a first line hormonal 
497 therapy and use of antioestrogens as an alternative therapy option highlighting results from 10 trials 
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498 using SERMs or SERDs as monotherapies between 1981 and 2013 (van Weelden et al. 2019).  
499 Studies all showed some beneficial response to therapy although results were variable and the 
500 authors concluded that Tamoxifen or a combination of tamoxifen and progestin might be the best 
501 choice when selecting second line hormonal treatment. In subsequent studies the SERM 
502 Ospemifene has been shown as an effective in treatment of vaginal symptoms in postmenopausal 
503 women (Archer, et al. 2019) and only acts as an agonist in endometrium in high doses. The SERD 
504 fulvestrant/faslodex (Table 2) has been investigated as a treatment for endometrial cancer in phase 
505 I/II trials, although well tolerated, it has low oral bioavailability and further trials are needed 
506 (Bogliolo, et al. 2017). Another recent study suggested dual targeting of ERα with tamoxifen and 
507 ERRα with XCT790 may be beneficial for EC treatment but this requires further validation (Mao, et 
508 al. 2019).
509 Whilst administration of SERMs/SERDs may be appropriate for postmenopausal women with 
510 cancer, their use in younger women with non-malignant endometrial disorders such as 
511 endometriosis is more challenging with data limited to promising results in preclinical models 
512 (Khine, et al. 2018; Kulak, et al. 2011). The observation that ERß is highly expressed in 
513 endometriosis lesions and the development of ERß-selective agonists such as ERß-041 with 
514 apparent anti-inflammatory properties provided a rationale for testing them as therapies for 
515 endometriosis with promising results obtained in pre-clinical models (Harris 2006). Several clinical 
516 trials were conducted with ERß-041 but no positive outcomes were reported. In a recent review 
517 Guo and Groothuis highlighted a number of reasons why drugs targeting ERß including the SERM 
518 Fulvestrant and ERß-041 failed to deliver the patient benefit in clinical trials. The reasons 
519 highlighted included, but were not limited to, animal models that did not recapitulate long-
520 established disease, translation of dose from rodent to women and incomplete understanding of the 
521 role of ERß antagonism in pain mechanisms (Guo and Groothuis 2018). SERMs are not considered 
522 suitable therapies for adenomyosis (Pontis et al. 2016). The SERM Ormeloxifene developed for use 
523 as a contraceptive, has also shown promising results in treating heavy menstrual bleeding (HMB) in 
524 perimenopausal women in India (Pati, et al. 2017). 
525 GPER has also been investigated as a target for treatment of endometriosis with reports that the 
526 GPER agonist G-1 induced cell cycle arrest and apoptosis of stromal cells derived from ovarian 
527 endometriosis cysts (Mori, et al. 2015). GPER has been implicated in E2-stimulated nociceptive 
528 pain in endometriosis with results in a mouse model showing administration of the selective GPER 
529 antagonist G36 inhibited the pain response (Alvarez, et al. 2014). Properly designed clinical trials 
530 are needed to explore GPER as a target for relief of painful symptoms in endometriosis in women. 
531 Targeting androgen receptors in endometrial disorders
532 The development of SARMs has prompted renewed interest in targeting of AR in reproductive 
533 disorders whilst also raising concerns related to side effects including hirsutism that are a hallmark 
534 of excess androgens in PCOS. Transgender individuals may be one group who might benefit from 
535 SARMs as administration of high concentrations of testosterone can result in abnormal uterine 
536 bleeding and metabolism to oestrogen may explain increased rates of endometrial cancer (Grimstad, 
537 et al. 2019) but there are no registered clinical trials. 
538 Danazol is a synthetic androgen first used as a treatment in the 1970s: it binds AR with high affinity 
539 and is also reported to reduce the activity of a number of enzymes including steroid sulphatase 
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540 (Carlstrom, et al. 1984). Danazol has anti-proliferative effects on uterine cells (Kauppila, et al. 
541 1985). A systematic review of RCTs using Danazol to treat endometriosis concluded that treatment 
542 was associated with reduced lesion size and relief of pain symptoms and women who took Danazol 
543 were more satisfied with their treatment compared with women who had placebo treatment (Selak, 
544 et al. 2007). The antiproliferative and hormone-suppressive activities of Danazol has formed the 
545 basis of treatments for adenomyosis (Vannuccini et al. 2018) and heavy menstrual bleeding 
546 (Beaumont, et al. 2007) with efficacy being demonstrated. The androgenic activity of Danazol is 
547 associated with side effects including hirsutism and deepening of the voice and it is contraindicated 
548 for women at risk of pregnancy because of the risk of virilisation of the fetus (Selak et al. 2007). 
549 These side effects have limited its use and prompted efforts to develop therapies that are less 
550 virilising.
551  Using a mouse model we have compared the impact of DHT with Danazol and new generation 
552 SARMs GTx-024 and GTx-007 (Table 2) and found that both Danazol and GTx-024 restored 
553 uterine weight of ovariectomised female mice to that of intact animals, while GTx-007 had no 
554 similar effect (Simitsidellis, et al. 2019). These preclinical studies highlight the importance of 
555 considering impacts on the endometrium when women are included in clinical trials using SARMs 
556 (Dalton et al. 2011; Neil, et al. 2018). Whilst SARMs have been used in clinical trials for treatment 
557 of breast cancer they have not as yet been tested as treatments for endometrial cancer or 
558 endometriosis (Narayanan, et al. 2018). Standard medical treatment for HMB involves targeting of 
559 the progesterone receptor either with the androgenic progestagen levonorgestrol delivered in an 
560 intra-uterine device or with newly developed selective progesterone receptor modulators (SPRMs; 
561 (Maybin and Critchley 2016)). Interestingly, administration of progesterone receptor antagonists or 
562 SPRMs such as UPA (ulipristal acetate) as a treatment for heavy menstrual bleeding results in a 
563 significant increase in expression of AR (Whitaker, et al. 2017) which may in part explain their 
564 antiproliferative action. Treatment with new generation SARMs is yet to be investigated.
565 Summary and Future Directions
566 The endometrium is a dynamic tissue which, by virtue of its expression of high affinity receptors, is 
567 exquisitely sensitive to the actions of oestrogens and androgens. Temporal and spatial changes in 
568 tissue function in response to steroids play a critical role in preparation for pregnancy and in 
569 breakdown and shedding if pregnancy does not occur. Balanced regulation of sex steroid action is 
570 essential for endometrial function and is controlled via local metabolism and cell- and tissue-
571 specific expression of steroid receptors/isoforms. Drugs targeting steroid metabolising enzyme 
572 activity and/or receptor function have reported efficacy in several endometrial disorders, but their 
573 use has often been limited due to lack of tissue specificity and undesirable side effect profiles. 
574 Recent development of drugs that selectively target steroid receptors such as next generation 
575 SERMs, SERDs, SARMs and SARDs show promise as new therapeutics but further pre-clinical 
576 studies and clinical trials are needed to determine if these drugs have efficacy specifically for the 
577 indication of endometrial disorders.
578
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1059 Table Legends
1060 Table 1. Hormone-dependent endometrial pathologies in women.
1061 For each pathology an estimate of incidence, hallmark features and one or two key references are 
1062 summarised.
1063
1064 Table 2. Non-steroidal drugs targeting oestrogen and androgen receptors.
1065 Each drug is identified by its common abbreviation or registered name, the activity as reported in 
1066 the literature, whether it has been used in one or more clinical trial(s) and a key reference is 
1067 provided. Abbreviations: PPT - 4,4',4''-(4-Propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol; DPN - 2,3-
1068 bis(4-Hydroxyphenyl)-propionitrile; GPER - G protein-coupled estrogen receptor 1; G36 - (±)-
1069 (3aR*,4S*,9bS*)-4-(6-Bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-tetrahydro-8-(1-methylethyl)-3H-
1070 cyclopenta[c]quinoline; SERM – selective oestrogen receptor modulator; SERD – selective 
1071 oestrogen receptor degrader; SARM – selective androgen receptor modulator
1072
1073
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1076 Figure Legends. 
1077 Figure 1. Expression of oestrogen receptor alpha (ERα) and androgen receptor (AR) in full 
1078 thickness samples from the human uterus.
1079 The tissue is divided into functional and basal layers supported on the myometrium below and 
1080 bounded on upper surface by the luminal epithelium. ERα (red stain) is abundant in epithelial cells 
1081 in the proliferative phase but down-regulated in the secretory phase. AR (green) is localised to 
1082 stromal cells in the basal and functional layers during the proliferative phase but only expressed in 
1083 the basal stromal cells in the secretory phase when its expression is upregulated in epithelial cells. P 
1084 – proliferative phase, S – secretory phase, M – menstrual phase. Adapted from Marshall et al 2011.
1085
1086 Figure 2. Simplified diagram of key biosynthetic steroids implicated in intracrine biosynthesis of 
1087 oestrogens and androgens within endometrial tissue.
1088 In pre-menopausal women both the adrenal and ovary are the primary sites of biosynthesis of 
1089 steroids. Expression of all enzymes illustrated has been validated in human tissue or primary 
1090 endometrial stromal cells exposed to a decidualisation stimulus (Gibson et al. 2013; Gibson et al. 
1091 2016a; Gibson et al. 2018b). For a more comprehensive steroidogenic pathway readers are referred 
1092 to the review by (Konings et al. 2018).
1093
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1 in 6 couples are infertile 
rates of implantation 
failure difficult to 
determine other than in 
IVF, RPL 1-2%
Poor/out of phase 
decidual response. 
Changes in immune cell 
cohorts (uNK?). Stromal 
cell senescence with age?
(Quenby et 
al. 2009); 




20-30% of women; may 
be worse during 
perimenopause; 
associated with fibroids
Acute or chronic; FIGO 





Endometriosis ~10% women of 
reproductive age; may be 
asymptomatic.
40% of infertile patients 
may have endometriosis
3 subtypes – aetiology 
may be different. 
Neuroinflammation and 





Horne, et al. 
2017) 
Adenomyosis ~20% in women in 
gynaecology clinics 
(higher in older women)
Growth of endometrial 
fragments within 
myometrial wall.







Estimates of incidence 
vary widely: 3 to 45 % in 
infertile population?
Adhesions within uterine 







Increase in gland to 
stroma ratio when 
compared with 
proliferative 
endometrium. Some types 





4th most common cancer 
in women UK; rates 
rising
Risk increased by high 
BMI and Lynch 
syndrome. Classifications 
based on histology or 
genetics with ‘unopposed’ 




(Ryan, et al. 
2017)
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Name Receptor activity Clinical Trials? References




(Frasor, et al. 2004)





(Greaves et al. 2013)
LNS8801 GPER agonist Phase 1 open label 
clinical trial in 
advanced solid and 
hematologic cancers.
NCT04130516
G36 GPER antagonist Improved selectivity 
compared to G15. 
(Dennis et al. 2011)
Tamoxifen SERM Treatment and 
prevention of ERα-
positive breast 



























SERM/SERD Positive impacts on 
bone, approved for 
HRT, SERD in 
endometrium
(Fanning et al. 2018)
GTx24, Enobosarm, SARM Muscle wasting in 
cancer, breast cancer, 
(Gao and Dalton 
2007)
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GTx007, Andarine, SARM, partial 
agonist
Tested in preclinical 
models; issues with 
use in doping
(Kearbey, et al. 
2007)
GSK2881078 SARM, long half life Muscle loss in 




mass in healthy 
women
(Neil et al. 2018)
AZD3514 SARD Moderate anti-
tumour activity in 
advanced castrate-
resistant PCa. 
Significant levels of 
nausea and vomiting.
(Omlin, et al. 2015)
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Figure 1. Expression of oestrogen receptor alpha (ERα) and androgen receptor (AR) in full thickness samples 
from the human uterus. 
The tissue is divided into functional and basal layers supported on the myometrium below and bounded on 
upper surface by the luminal epithelium. ERα (red stain) is abundant in epithelial cells in the proliferative 
phase but down-regulated in the secretory phase. AR (green) is localised to stromal cells in the basal and 
functional layers during the proliferative phase but only expressed in the basal stromal cells in the secretory 
phase when its expression is upregulated in epithelial cells. P – proliferative phase, S – secretory phase, M – 
menstrual phase. Adapted from Marshall et al 2011. 
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Figure 2. Simplified diagram of key biosynthetic steroids implicated in intracrine biosynthesis of oestrogens 
and androgens within endometrial tissue. 
In pre-menopausal women both the adrenal and ovary are the primary sites of biosynthesis of steroids. 
Expression of all enzymes illustrated has been validated in human tissue or primary endometrial stromal 
cells exposed to a decidualisation stimulus (Gibson et al. 2013; Gibson et al. 2016a; Gibson et al. 2018b). 
For a more comprehensive steroidogenic pathway readers are referred to the review by (Konings et al. 
2018). 
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